198 related articles for article (PubMed ID: 28133055)
1. [Analysis of the Risk Factors of Febrile Neutropenia Among 72 Women Receiving FEC in Early Breast Cancer Chemotherapy].
Ishii N; Fujimori T; Kasagawa T; Udagawa I
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1555-1557. PubMed ID: 28133055
[TBL] [Abstract][Full Text] [Related]
2. Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment.
Assi H; Murray J; Boyle L; Rayson D
Support Care Cancer; 2014 Dec; 22(12):3227-34. PubMed ID: 24996828
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D.
Lee EK; Wong WW; Trudeau ME; Chan KK
Breast Cancer Res Treat; 2015 Feb; 150(1):169-80. PubMed ID: 25694355
[TBL] [Abstract][Full Text] [Related]
4. Febrile neutropenia in FEC-D regimen for early stage breast cancer: is there a place for G-CSF primary prophylaxis?
Miguel I; Winckler P; Sousa M; Cardoso C; Moreira A; Brito M
Breast Dis; 2015; 35(3):167-71. PubMed ID: 26406541
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study.
Sakurada T; Bando S; Zamami Y; Takechi K; Chuma M; Goda M; Kirino Y; Nakamura T; Teraoka K; Morimoto M; Tangoku A; Ishizawa K
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1107-1114. PubMed ID: 31502114
[TBL] [Abstract][Full Text] [Related]
6. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
Mäenpää J; Varthalitis I; Erdkamp F; Trojan A; Krzemieniecki K; Lindman H; Bendall K; Vogl FD; Verma S
Breast; 2016 Feb; 25():27-33. PubMed ID: 26801413
[TBL] [Abstract][Full Text] [Related]
7. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
[TBL] [Abstract][Full Text] [Related]
8. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
Ottosson S; Magnusson K; Hultborn R
Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
[TBL] [Abstract][Full Text] [Related]
9. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
Skedgel C; Rayson D; Younis T
Support Care Cancer; 2016 Jan; 24(1):387-394. PubMed ID: 26081595
[TBL] [Abstract][Full Text] [Related]
10. The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.
Do T; Medhekar R; Bhat R; Chen H; Niravath P; Trivedi MV
Breast Cancer Res Treat; 2015 Oct; 153(3):591-7. PubMed ID: 26337685
[TBL] [Abstract][Full Text] [Related]
11. Reducing febrile neutropenia rates in early breast cancer. Experience of two UK cancer centres.
Mullard AP; Misra V; Sumra P; Ali Z; O'Reilly SM; Malik Z
Support Care Cancer; 2014 Aug; 22(8):2033-7. PubMed ID: 24595405
[TBL] [Abstract][Full Text] [Related]
12. [Influence of Next-Day Administration of Pegfilgrastim after FEC100 Chemotherapy in Japanese with Breast Cancer on Neutrophil Count].
Fujiwara D; Mashimo K; Kimura K; Noda A; Taki K; Yoshibayashi H; Takeda T; Tsubaki M; Nishida S; Sakaguchi K
Gan To Kagaku Ryoho; 2017 Feb; 44(2):149-152. PubMed ID: 28223672
[TBL] [Abstract][Full Text] [Related]
13. Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer.
Kimura Y; Sasada S; Emi A; Masumoto N; Kadoya T; Okada M
Support Care Cancer; 2021 Jul; 29(7):3507-3512. PubMed ID: 33146835
[TBL] [Abstract][Full Text] [Related]
14. Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study.
Ishikawa T; Sakamaki K; Narui K; Nishimura H; Sangai T; Tamaki K; Hasegawa Y; Watanabe KI; Suganuma N; Michishita S; Sugae S; Aihara T; Tsugawa K; Kaise H; Taira N; Mukai H;
Breast; 2021 Apr; 56():70-77. PubMed ID: 33631458
[TBL] [Abstract][Full Text] [Related]
15. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
Aarts MJ; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Borm GF; Tjan-Heijnen VC
J Clin Oncol; 2013 Dec; 31(34):4290-6. PubMed ID: 23630211
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.
Younis T; Rayson D; Jovanovic S; Skedgel C
Breast Cancer Res Treat; 2016 Oct; 159(3):425-32. PubMed ID: 27572552
[TBL] [Abstract][Full Text] [Related]
18. Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.
Fernandes R; Mazzarello S; Stober C; Vandermeer L; Dudani S; Ibrahim MF; Majeed H; Perdrizet K; Shorr R; Hutton B; Fergusson D; Clemons M
Breast Cancer Res Treat; 2017 Jan; 161(1):1-10. PubMed ID: 27783280
[TBL] [Abstract][Full Text] [Related]
19. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).
Vulsteke C; Lambrechts D; Dieudonné A; Hatse S; Brouwers B; van Brussel T; Neven P; Belmans A; Schöffski P; Paridaens R; Wildiers H
Ann Oncol; 2013 Jun; 24(6):1513-25. PubMed ID: 23396606
[TBL] [Abstract][Full Text] [Related]
20. Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review.
Fernandes R; Mazzarello S; Stober C; Ibrahim MFK; Dudani S; Perdrizet K; Majeed H; Vandermeer L; Shorr R; Hutton B; Fergusson D; Gyawali B; Clemons M
J Glob Oncol; 2018 Sep; 4():1-8. PubMed ID: 30241156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]